Nexam Chemical receives additional letters of intent of approximately SEK 6.5 million in ongoing Rights Issue

Nexam Chemical's SEK 51.8 million rights issue has received additional letters of intent of approximately SEK 6.5 million from three major existing shareholders (SEK 3.1m pro rata and ~SEK 3.4m additional), representing about 12.5% of the offer. Together with prior subscription undertakings of ~SEK 11.4 million (22.1%) and underwriting commitments of ~SEK 40.4 million (77.9%), the rights issue is fully covered; letters, undertakings and underwritings carry no compensation or bank guarantees. The subscription period runs until February 9, 2026, and the new commitments reduce the underwriters' maximum allocation, indicating strong insider and underwriter support but imminent dilution for existing holders.

Analysis

Market structure: The Rights Issue (SEK 51.8m) being fully covered by ~77.9% underwriting and ~34.6% insider/major-holder intent (combined commitments) signals near-term liquidity certainty for Nexam Chemical but limited fresh market-driven demand. Winners: existing shareholders who subscribe pro rata (avoid dilution) and underwriters who capture fees; losers: retail holders who do not participate and may see dilution if they sit out. Expect muted price upside until proceeds are deployed and operational milestones are visible (3–12 months).

Risk assessment: Key tail risks are underwriter non-performance (commitments not bank-guaranteed), FDI screening delays (Swedish rule) that could restrict certain investors, and execution risk converting proceeds into revenue — each could trigger >30–50% downside in extreme scenarios. Immediate (days): subscription window volatility around Feb 9, 2026; short-term (weeks–months): post-issue dilution and sell-down; long-term (quarters): revenue lift if product adoption ramps. Hidden dependency: concentration of insider commitments (>22%) may signal limited external demand rather than confidence.

Trade implications: If you can access the issue, selectively subscribe pro rata to preserve ownership (recommend max 1–3% portfolio exposure) and avoid open-market dilution. If not participating, wait for post-issue liquidity and buy on weakness: initiate long only if share price trades ≥15% below theoretical ex-rights price (TERP) with a 25% stop. Hedging: offset sector beta with a short position in large-cap chemical peers (e.g., EVK.DE or BAS.DE) sized 50–70% of equity exposure.

Contrarian angle: The market consensus will view “fully covered” as safety; it ignores that underwriting lacks guarantees and that insiders dominate demand — a funding safety net that can still leave fundamentals unchanged. Historical parallels: microcap rights backed by underwriters often lead to initial stabilization then multi-month underperformance if proceeds are used for working capital rather than clear revenue-generating initiatives. Catalyst watch: subscription close (Feb 9), any announcement of use-of-proceeds milestones within 90 days, and FDI screening outcomes.

Key Decisions for Investors

• If you are an existing shareholder: participate pro rata in the Rights Issue up to your allocation to avoid ~>10–20% dilution; limit incremental cash to keep total position at 1–3% of portfolio and require a written use-of-proceeds milestone within 90 days before adding further exposure.
• If you are not participating: establish a tactical long position in Nexam Chemical (size 1–2% of portfolio) only after the issue closes and if the share price is ≥15% below TERP; use a 25% stop-loss and hedge 50–70% of beta risk by shorting Evonik (EVK.DE) or BASF (BAS.DE).
• Options/vol strategy: if liquid equities options exist, buy a 3–6 month put spread (e.g., 25–40% OTM) to protect a new long or sell a small amount of OTM covered calls 6–12 weeks post-issue to monetize potential range-bound action; avoid uncovered shorts.
• Risk-control monitor: within 30 days track (a) underwriter confirmation of funded subscriptions, (b) any FDI screening flags, and (c) a detailed 90-day use-of-proceeds/operational milestone schedule — reduce exposure by 50% if any of these are negative or delayed.